Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1

被引:9
|
作者
Wang, Tiantian [1 ,2 ]
Pang, Lidan [1 ]
He, Mengni [1 ]
Wang, Zengtao [1 ]
机构
[1] Jiangxi Univ Chinese Med, Coll Pharm, Nanchang 330004, Peoples R China
[2] Jiangxi Univ Chinese Med, Natl Pharmaceut Engn Ctr Solid Preparat Chinese He, Nanchang 330006, Peoples R China
关键词
ASK1; inhibitors; Reviews; Optimization strategies; Structure-activity relationships; ENDOPLASMIC-RETICULUM STRESS; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; NEURONAL CELL-DEATH; ASK1; INHIBITOR; INCREASED VULNERABILITY; DEPENDENT ACTIVATION; HIPPOCAMPAL-NEURONS; CRYSTAL-STRUCTURES; STRUCTURAL BASIS;
D O I
10.1016/j.ejmech.2023.115889
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Apoptosis signal regulated kinase 1 (ASK1, also known as MAP3K5) is a member of the mitogen activated protein kinase kinase kinase (MAP3K) family. Since its first isolation from a human macrophage library in 1996, its research has been ongoing for over 25 years. A large number of reports have revealed that ASK1, as a key activator of the p38 mitogen-activated protein kinase and c-Jun N-terminal kinase (JNK) signaling cascade, responds to various stressors, and its inhibitors have important potential value in the treatment of diseases such as inflammation, cancer, and the nervous system and so on. This review summarizes the recent development in this field, including the structure and signaling pathways of ASK1, with a particular focus on the structureactivity relationships, and the hit-to-lead optimization strategies.
引用
收藏
页数:31
相关论文
共 50 条
  • [31] Targeting the transcription factor Myb by small-molecule inhibitors
    Uttarkar, Sagar
    Frarnpton, Jon
    Klempnauer, Karl-Heinz
    EXPERIMENTAL HEMATOLOGY, 2017, 47 : 31 - 35
  • [32] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
    Singh, Mahaveer
    Jadhav, Hemant R.
    DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
  • [33] An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors
    Moolman, Chantalle
    van der Sluis, Rencia
    Beteck, Richard M.
    Legoabe, Lesetja J.
    MOLECULES, 2020, 25 (21):
  • [34] Targeting cancer with small molecule kinase inhibitors
    Jianming Zhang
    Priscilla L. Yang
    Nathanael S. Gray
    Nature Reviews Cancer, 2009, 9 : 28 - 39
  • [35] Targeting cancer with small molecule kinase inhibitors
    Zhang, Jianming
    Yang, Priscilla L.
    Gray, Nathanael S.
    NATURE REVIEWS CANCER, 2009, 9 (01) : 28 - 39
  • [36] Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors
    Panicker, Resmi C.
    Chattopadhaya, Souvik
    Coyne, Anthony G.
    Srinivasan, Rajavel
    PROTEIN ALLOSTERY IN DRUG DISCOVERY, 2019, 1163 : 253 - 278
  • [37] FDA-approved small-molecule kinase inhibitors
    Wu, Peng
    Nielsen, Thomas E.
    Clausen, Mads H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) : 422 - 439
  • [38] Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
    Xie, Zhouling
    Yang, Xiaoxiao
    Duan, Yajun
    Han, Jihong
    Liao, Chenzhong
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (03) : 1283 - 1345
  • [39] Ventilation-induced neutrophil infiltration and apoptosis depend on apoptosis signal-regulated kinase 1 pathway
    Li, Li-Fu
    Liao, Shuen-Kuei
    Lee, Cheng-Huei
    Tsai, Ying-Huang
    Huang, Chung-Chi
    Quinn, Deborah A.
    CRITICAL CARE MEDICINE, 2005, 33 (09) : 1913 - 1921
  • [40] Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain
    Shirish Shukla
    Weijiang Ying
    Felicia Gray
    Yiwu Yao
    Miranda L. Simes
    Qingjie Zhao
    Hongzhi Miao
    Hyo Je Cho
    Paula González-Alonso
    Alyssa Winkler
    George Lund
    Trupta Purohit
    EunGi Kim
    Xiaotian Zhang
    Joshua M. Ray
    Shihan He
    Caroline Nikolaidis
    Juliano Ndoj
    Jingya Wang
    Łukasz Jaremko
    Mariusz Jaremko
    Russell J. H. Ryan
    Monica L. Guzman
    Jolanta Grembecka
    Tomasz Cierpicki
    Nature Chemical Biology, 2021, 17 : 784 - 793